Bahreiny Seyed Sobhan, Ahangarpour Akram, Aghaei Mojtaba, Mohammadpour Fard Reza, Jalali Far Mohammad Ali, Sakhavarz Tannaz
Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Diabetes Metab Disord. 2024 Jul 6;23(2):1621-1633. doi: 10.1007/s40200-024-01461-z. eCollection 2024 Dec.
Gestational diabetes mellitus (GDM) represents a significant metabolic disorder that affects pregnant women worldwide and has negative consequences for both the mother and her offspring. This research aims to investigate the relation between circulating levels of Galectin-3 and the incidence of GDM, and to evaluate its potential as a biomarker for monitoring and early detection of the disease.
A thorough search of the literature has been performed using databases such as Scopus, Web of science, Embase, Cochrane Library and PubMed. The standardized mean difference (SMD) and corresponding confidence intervals (CIs) were used to compute the effect size from individual records and pooled using the Random-effect model.
Our meta-analysis synthesized data from 9 studies, encompassing 1,286 participants (533 GDM patients and 753 healthy pregnant controls). The findings demonstrated a considerable increase in Galectin-3 levels among individuals diagnosed with GDM as compared to the healthy control (SMD = 0.929; CI: 0.179-1.679; = 0.015), with observed heterogeneity (I = 87%; < 0.001). Subgroup analyses revealed the influence of factors such as age, BMI, study design, and sample type on Galectin-3 levels. A meta-regression analysis further identified trends indicating that levels of Galectin-3 are linked to gestational age, specific geographical areas, and sample size.
Increased levels of Galectin-3 exhibit a significant association with GDM, indicating its prospective utility as a biomarker for early detection and risk assessment. Further research is warranted to elucidate its regulation and clinical implications in GDM management.
The online version contains supplementary material available at 10.1007/s40200-024-01461-z.
妊娠期糖尿病（GDM）是一种严重的代谢紊乱疾病，影响着全球的孕妇，对母亲及其后代都会产生不良后果。本研究旨在探讨半乳糖凝集素-3循环水平与GDM发病率之间的关系，并评估其作为该疾病监测和早期检测生物标志物的潜力。
使用Scopus、科学网、Embase、Cochrane图书馆和PubMed等数据库对文献进行了全面检索。采用标准化均值差（SMD）和相应的置信区间（CIs）来计算个体记录的效应大小，并使用随机效应模型进行汇总。
我们的荟萃分析综合了9项研究的数据，涵盖1286名参与者（533名GDM患者和753名健康孕妇对照）。研究结果表明，与健康对照相比，被诊断为GDM的个体中半乳糖凝集素-3水平显著升高（SMD = 0.929；CI：0.179 - 1.679；P = 0.015），观察到存在异质性（I² = 87%；P < 0.001）。亚组分析揭示了年龄、BMI、研究设计和样本类型等因素对半乳糖凝集素-3水平的影响。荟萃回归分析进一步确定了趋势，表明半乳糖凝集素-3水平与孕周、特定地理区域和样本量有关。
半乳糖凝集素-3水平升高与GDM显著相关，表明其作为早期检测和风险评估生物标志物的潜在效用。有必要进一步研究以阐明其在GDM管理中的调节作用和临床意义。
在线版本包含可在10.1007/s40200-024-01461-z获取补充材料。
